[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1)

Request For Quotation
[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1) Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Shanghai Rechem science Co., Ltd.  
Tel: 021-31433387 15618786686
Email: sales@rechemscience.com
Company Name: Shanghai Yifei Biotechnology Co. , Ltd.  
Tel: 021-65675885 18964387627
Email: customer_service@efebio.com
Company Name: RD International Technology Co., Limited  
Tel: 18024082417
Email: market@ubiochem.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1) Basic information
Product Name:[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1)
Synonyms:[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1);BB-C-Amidine(hydrochloride)
CAS:2436747-41-8
MF:C26H27Cl2N5O
MW:496.44
EINECS:
Product Categories:
Mol File:2436747-41-8.mol
[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1) Structure
[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1) Chemical Properties
form Solid
color White to off-white
Safety Information
MSDS Information
[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1) Usage And Synthesis
UsesBB-Cl-Amidine hydrochloride is a peptidylarginine deminase (PAD) inhibitor[1].
in vivo

Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. Indeed, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely[1].

Animal Model:MRL/lpr mice[1].
Dosage:1 mg/kg.
Administration:Subcutaneous injection daily from 8 to 14 weeks of age.
Result:Significantly improved endothelium-dependent vasorelaxation and showed a strong trend towards downregulation of IRGs.
References[1] Knight JS, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis. 2015 Dec;74(12):2199-206. DOI:10.1136/annrheumdis-2014-205365
[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1) Preparation Products And Raw materials
Tag:[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1)(2436747-41-8) Related Product Information
N-[1-(1H-1,3-Benzimidazol-2-yl)-3-methylbutyl]benzenecarboxamide BB-Cl-Amidine hydrochloride BB-F-Yne [1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1) NA Photoswitchable PAD Inhibitor (technical grade)